Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Masked, Controlled Study of Squalamine Lactate (MSI-1256F) for Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

NCT00139282 is registered in ClinicalTrials.gov with Genaera Corporation as lead sponsor.

NCT NCT00139282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00139282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Masked, Controlled Study of Squalamine Lactate (MSI-1256F) for Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
Lead sponsor
Genaera Corporation
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2005
Completion date
Not reported
Enrollment
Not reported
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

"wet" age-related macular degeneration